Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Oncogene Retrieve available abstracts of 68 articles: HTML format

Single Articles

April 2024
1. REGER DE MOURA C, Louveau B, Jouenne F, Vilquin P, et al
   Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1.
   Oncogene. 2024 Apr 3. doi: 10.1038/s41388-024-03014.
   PubMed     Abstract available
   
   
   March 2024
2. DURAND S, Tang Y, Pommier RM, Benboubker V, et al
   ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions.
   Oncogene. 2024 Mar 22. doi: 10.1038/s41388-024-03010.
   PubMed     Abstract available
   
   
   February 2024
3. XIAO Y, Zhou L, Andl T, Zhang Y, et al
   YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression.
   Oncogene. 2024 Feb 2. doi: 10.1038/s41388-024-02953.
   PubMed     Abstract available
   
   
   
4. JESSEN M, Gertzmann D, Liss F, Zenk F, et al
   Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.
   Oncogene. 2024;43:578-593.
   PubMed     Abstract available
   
   
   January 2024
5. CANNON AC, Budagyan K, Uribe-Alvarez C, Kurimchak AM, et al
   Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
   Oncogene. 2024 Jan 19. doi: 10.1038/s41388-024-02947.
   PubMed     Abstract available
   
   
   December 2023
6. HAN S, Zhang M, Qu X, Wu Z, et al
   SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma.
   Oncogene. 2023 Dec 15. doi: 10.1038/s41388-023-02917.
   PubMed     Abstract available
   
   
   
7. JAGIRDAR K, Portuallo ME, Wei M, Wilhide M, et al
   ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
   Oncogene. 2023 Dec 8. doi: 10.1038/s41388-023-02900.
   PubMed     Abstract available
   
   
   November 2023
8. KURTENBACH S, Sanchez MI, Kuznetsoff J, Rodriguez DA, et al
   PRAME induces genomic instability in uveal melanoma.
   Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02887.
   PubMed     Abstract available
   
   
   September 2023
9. LUO Y, Zhu Q, Xiang S, Wang Q, et al
   Downregulated circPOKE promotes breast cancer metastasis through activation of the USP10-Snail axis.
   Oncogene. 2023 Sep 16. doi: 10.1038/s41388-023-02823.
   PubMed     Abstract available
   
   
   
10. RICHARDS JR, Shin D, Pryor R, Sorensen LK, et al
    Correction: Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis.
    Oncogene. 2023 Sep 8. doi: 10.1038/s41388-023-02828.
    PubMed    
    
    
    
11. SHINZAWA K, Matsumoto S, Sada R, Harada A, et al
    GREB1 isoform 4 is specifically transcribed by MITF and required for melanoma proliferation.
    Oncogene. 2023 Sep 1. doi: 10.1038/s41388-023-02803.
    PubMed     Abstract available
    
    
    July 2023
12. ARUMI-PLANAS M, Rodriguez-Baena FJ, Cabello-Torres F, Gracia F, et al
    Microenvironmental Snail1-induced immunosuppression promotes melanoma growth.
    Oncogene. 2023 Jul 29. doi: 10.1038/s41388-023-02793.
    PubMed     Abstract available
    
    
    
13. RICHARDS JR, Shin D, Pryor R, Sorensen LK, et al
    Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis.
    Oncogene. 2023 Jul 27. doi: 10.1038/s41388-023-02792.
    PubMed     Abstract available
    
    
    June 2023
14. LUO R, Chyr J, Wen J, Wang Y, et al
    A novel integrated approach to predicting cancer immunotherapy efficacy.
    Oncogene. 2023;42:1913-1925.
    PubMed     Abstract available
    
    
    March 2023
15. MALVI P, Reddy DS, Kumar R, Chava S, et al
    LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.
    Oncogene. 2023 Mar 16. doi: 10.1038/s41388-023-02658.
    PubMed     Abstract available
    
    
    
16. KUSER-ABALI G, Zhang Y, Szeto P, Zhao P, et al
    UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma.
    Oncogene. 2023 Mar 11. doi: 10.1038/s41388-023-02631.
    PubMed     Abstract available
    
    
    
17. DING Y, Chen J, Li S, Wren JD, et al
    EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy.
    Oncogene. 2023;42:861-868.
    PubMed     Abstract available
    
    
    February 2023
18. SONG D, Cismas S, Crudden C, Trocme E, et al
    Correction: IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02607.
    PubMed    
    
    
    December 2022
19. ZHOU B, Basu J, Kazmi HR, Chitrala KN, et al
    Interferon-gamma signaling promotes melanoma progression and metastasis.
    Oncogene. 2022 Dec 3. doi: 10.1038/s41388-022-02561.
    PubMed     Abstract available
    
    
    November 2022
20. FATTORE L, Cafaro G, Di Martile M, Campani V, et al
    Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.
    Oncogene. 2022 Nov 23. doi: 10.1038/s41388-022-02547.
    PubMed     Abstract available
    
    
    October 2022
21. TAPMEIER TT, Howell JH, Zhao L, Papiez BW, et al
    Evolving polarisation of infiltrating and alveolar macrophages in the lung during metastatic progression of melanoma suggests CCR1 as a therapeutic target.
    Oncogene. 2022 Oct 14. pii: 10.1038/s41388-022-02488.
    PubMed     Abstract available
    
    
    
22. ZIMMERMAN SM, Nixon SJ, Chen PY, Raj L, et al
    Ezh2(Y641F) mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma.
    Oncogene. 2022 Oct 11. pii: 10.1038/s41388-022-02492.
    PubMed     Abstract available
    
    
    July 2022
23. DIETER SM, Lovecchio D, Pataskar A, Zowada MK, et al
    Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors.
    Oncogene. 2022 Jul 7. pii: 10.1038/s41388-022-02400.
    PubMed     Abstract available
    
    
    June 2022
24. LI Y, Yang J, Zhang Q, Xu S, et al
    Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Oncogene. 2022 Jun 13. pii: 10.1038/s41388-022-02364.
    PubMed     Abstract available
    
    
    May 2022
25. MANCUSO P, Tricarico R, Bhattacharjee V, Cosentino L, et al
    Correction to: Thymine DNA glycosylase as a novel target for melanoma.
    Oncogene. 2022 May 3. pii: 10.1038/s41388-022-02335.
    PubMed    
    
    
    March 2022
26. SALA M, Allain N, Moreau M, Jabouille A, et al
    Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
    Oncogene. 2022 Mar 23. pii: 10.1038/s41388-022-02266.
    PubMed     Abstract available
    
    
    February 2022
27. LANDRAS A, Reger de Moura C, Villoutreix BO, Battistella M, et al
    Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
    Oncogene. 2022 Feb 26. pii: 10.1038/s41388-022-02244.
    PubMed     Abstract available
    
    
    
28. XU Y, He X, Wang S, Sun B, et al
    The m(6)A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation.
    Oncogene. 2022 Feb 3. pii: 10.1038/s41388-021-02146.
    PubMed     Abstract available
    
    
    January 2022
29. HAN A, Chua V, Baqai U, Purwin TJ, et al
    Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02154.
    PubMed     Abstract available
    
    
    November 2021
30. SONG D, Cismas S, Crudden C, Trocme E, et al
    IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.
    Oncogene. 2021 Nov 17. pii: 10.1038/s41388-021-02111.
    PubMed     Abstract available
    
    
    
31. SHIN Y, Kim S, Ghate NB, Rhie SK, et al
    MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis.
    Oncogene. 2021 Nov 16. pii: 10.1038/s41388-021-02109.
    PubMed     Abstract available
    
    
    
32. DEWAELE S, Delhaye L, De Paepe B, de Bony EJ, et al
    Correction to: The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.
    Oncogene. 2021 Nov 15. pii: 10.1038/s41388-021-02051.
    PubMed    
    
    
    October 2021
33. LEONARD MK, Puts GS, Pamidimukkala N, Adhikary G, et al
    Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
    Oncogene. 2021 Oct 11. pii: 10.1038/s41388-021-02045.
    PubMed    
    
    
    
34. KYJACOVA L, Saup R, Ronsch K, Wallbaum S, et al
    IER2-induced senescence drives melanoma invasion through osteopontin.
    Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02027.
    PubMed     Abstract available
    
    
    
35. SOSHNIKOVA NV, Tatarskiy EV, Tatarskiy VV, Klimenko NS, et al
    PHF10 subunit of PBAF complex mediates transcriptional activation by MYC.
    Oncogene. 2021;40:6071-6080.
    PubMed     Abstract available
    
    
    September 2021
36. DEWAELE S, Delhaye L, De Paepe B, de Bony EJ, et al
    The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.
    Oncogene. 2021 Sep 10. pii: 10.1038/s41388-021-02006.
    PubMed     Abstract available
    
    
    August 2021
37. LEONARD MK, Puts GS, Pamidimukkala N, Adhikary G, et al
    Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
    Oncogene. 2021 Aug 25. pii: 10.1038/s41388-021-01998.
    PubMed     Abstract available
    
    
    July 2021
38. MECOZZI N, Vera O, Karreth FA
    Squaring the circle: circRNAs in melanoma.
    Oncogene. 2021 Jul 30. pii: 10.1038/s41388-021-01977.
    PubMed     Abstract available
    
    
    
39. HE S, Zimmerman MW, Layden HM, Berezovskaya A, et al
    Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss.
    Oncogene. 2021 Jul 30. pii: 10.1038/s41388-021-01926.
    PubMed     Abstract available
    
    
    
40. HUANG S, Deng W, Wang P, Yan Y, et al
    Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-alpha-Pix to Rac1 to activate the MAPK pathway.
    Oncogene. 2021 Jul 28. pii: 10.1038/s41388-021-01954.
    PubMed     Abstract available
    
    
    
41. WANG B, Zhang W, Zhang G, Kwong L, et al
    Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
    Oncogene. 2021 Jul 24. pii: 10.1038/s41388-021-01911.
    PubMed     Abstract available
    
    
    
42. BI O, Anene CA, Nsengimana J, Shelton M, et al
    SFPQ promotes an oncogenic transcriptomic state in melanoma.
    Oncogene. 2021 Jul 3. pii: 10.1038/s41388-021-01912.
    PubMed     Abstract available
    
    
    
43. KALUZ S, Zhang Q, Kuranaga Y, Yang H, et al
    Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
    Oncogene. 2021 Jul 3. pii: 10.1038/s41388-021-01919.
    PubMed     Abstract available
    
    
    June 2021
44. LEQUEUX A, Noman MZ, Xiao M, Van Moer K, et al
    Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01846.
    PubMed     Abstract available
    
    
    
45. OTTINA E, Panova V, Doglio L, Kazachenka A, et al
    E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
    Oncogene. 2021 Jun 18. pii: 10.1038/s41388-021-01885.
    PubMed     Abstract available
    
    
    
46. ALONSO-MARANON J, Villanueva A, Piulats JM, Martinez-Iniesta M, et al
    Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair.
    Oncogene. 2021 Jun 17. pii: 10.1038/s41388-021-01879.
    PubMed     Abstract available
    
    
    May 2021
47. ZHANG F, Tang X, Fan S, Liu X, et al
    Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors.
    Oncogene. 2021 May 20. pii: 10.1038/s41388-021-01834.
    PubMed     Abstract available
    
    
    
48. PIETROBONO S, Gaudio E, Gagliardi S, Zitani M, et al
    Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01783.
    PubMed     Abstract available
    
    
    
49. BILLING O, Holmgren Y, Nosek D, Hedman H, et al
    LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
    Oncogene. 2021 May 4. pii: 10.1038/s41388-021-01808.
    PubMed     Abstract available
    
    
    April 2021
50. KAKUMANI PK, Guitart T, Houle F, Harvey LM, et al
    CSDE1 attenuates microRNA-mediated silencing of PMEPA1 in melanoma.
    Oncogene. 2021 Apr 8. pii: 10.1038/s41388-021-01767.
    PubMed     Abstract available
    
    
    March 2021
51. RAWAT V, Malvi P, Della Manna D, Yang ES, et al
    PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01683.
    PubMed     Abstract available
    
    
    
52. SULLIVAN RJ, Flaherty K
    Correction to: MAP kinase signaling and inhibition in melanoma.
    Oncogene. 2021 Mar 3. pii: 10.1038/s41388-021-01716.
    PubMed    
    
    
    
53. LI X, Su X, Liu R, Pan Y, et al
    HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression.
    Oncogene. 2021;40:1836-1850.
    PubMed     Abstract available
    
    
    February 2021
54. ZHANG X, Huang Z, Guo Y, Xiao T, et al
    Correction to: The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis.
    Oncogene. 2021 Feb 22. pii: 10.1038/s41388-021-01641.
    PubMed    
    
    
    
55. NETANELY D, Leibou S, Parikh R, Stern N, et al
    Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01665.
    PubMed     Abstract available
    
    
    January 2021
56. HAN A, Purwin TJ, Bechtel N, Liao C, et al
    Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
    Oncogene. 2021 Jan 28. pii: 10.1038/s41388-021-01645.
    PubMed    
    
    
    
57. SCHAFER A, Haenig B, Erupathil J, Strickner P, et al
    Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.
    Oncogene. 2021 Jan 26. pii: 10.1038/s41388-020-01628.
    PubMed     Abstract available
    
    
    December 2020
58. SWOBODA A, Soukup R, Eckel O, Kinslechner K, et al
    STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01584.
    PubMed     Abstract available
    
    
    
59. JESSEN C, Kress JKC, Baluapuri A, Hufnagel A, et al
    Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.
    Oncogene. 2020 Dec 1. pii: 10.1038/s41388-020-01535.
    PubMed     Abstract available
    
    
    
60. MA J, Weng L, Bastian BC, Chen X, et al
    Functional characterization of uveal melanoma oncogenes.
    Oncogene. 2020 Dec 1. pii: 10.1038/s41388-020-01569.
    PubMed     Abstract available
    
    
    November 2020
61. HAN A, Purwin TJ, Bechtel N, Liao C, et al
    BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
    Oncogene. 2020 Nov 18. pii: 10.1038/s41388-020-01554.
    PubMed     Abstract available
    
    
    October 2020
62. GUPTA R, Janostiak R, Wajapeyee N
    Transcriptional regulators and alterations that drive melanoma initiation and progression.
    Oncogene. 2020 Oct 6. pii: 10.1038/s41388-020-01490.
    PubMed     Abstract available
    
    
    
63. AZAD AK, Zhabyeyev P, Vanhaesebroeck B, Eitzen G, et al
    Inactivation of endothelial cell phosphoinositide 3-kinase beta inhibits tumor angiogenesis and tumor growth.
    Oncogene. 2020;39:6480-6492.
    PubMed     Abstract available
    
    
    September 2020
64. BROGGINI T, Piffko A, Hoffmann CJ, Ghori A, et al
    Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01473.
    PubMed     Abstract available
    
    
    
65. JESSEN C, Kress JKC, Baluapuri A, Hufnagel A, et al
    The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.
    Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01477.
    PubMed     Abstract available
    
    
    May 2020
66. BRUMMER T, McInnes C
    RAF kinase dimerization: implications for drug discovery and clinical outcomes.
    Oncogene. 2020;39:4155-4169.
    PubMed     Abstract available
    
    
    
67. CHAO HH, Karagounis IV, Thomas C, Francois NB, et al
    Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation.
    Oncogene. 2020;39:4344-4357.
    PubMed     Abstract available
    
    
    April 2020
68. DIAZ-VALDIVIA NI, Diaz J, Contreras P, Campos A, et al
    The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
    Oncogene. 2020;39:3693-3709.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.